Skip to main content
. 2021 Oct 14;28(5):4157–4166. doi: 10.3390/curroncol28050352

Figure 3.

Figure 3

Response to atezolizumab + bevacizumab combination therapy in patients with hepatocellular carcinoma (HCC) caused by hepatitis virus infection and those with non-viral HCC (CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; HBV, hepatitis B virus; HCV, hepatitis C virus).